$HAE (Haemonetics Corporation)

$HAE {{ '2016-04-14T20:19:38+0000' | timeago}} • Announcement

Healthcare company $HAE said Christopher Lindop, CFO and EVP, Business Development has announced his retirement from the company effective May 27, 2016. The company stated it will immediately begin a search for Mr. Lindop's successor.

$GILD {{ '2017-09-26T13:43:32+0000' | timeago}} • Announcement

$GILD and $KITE announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to $GILD’s cash tender offer for $KITE expired on September 25, 2017. With the expiration of the waiting period, the tender offer is expected to close in the beginning of October 2017, subject to closing conditions.

$LIVN {{ '2017-09-25T16:00:14+0000' | timeago}} • Announcement

$LIVN got FDA 510(k) clearance for the US market launch of its Optiflow Arterial Cannulae family. Optiflow aortic arch cannulae provide improved hydrodynamics with a novel dispersive tip design that improves blood flow characteristics resulting in reduced wall shear stress profiles and thereby reducing complications during cardiac surgery.

$AGN {{ '2017-09-25T15:26:35+0000' | timeago}} • Announcement

$AGN CFO Tessa Hilado has decided to retire from the company. Allergan has initiated a search to fill the position. Hilado, who joined the company in Dec 2014, will continue in her current role until a successor is named to ensure a smooth transition.

$BIIB {{ '2017-09-25T14:11:23+0000' | timeago}} • Announcement

$BIIB appointed Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective immediately. In this new role, she will report directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D. and will be based in Cambridge.

$LLY {{ '2017-09-25T13:18:33+0000' | timeago}} • Announcement

Geisinger and Boehringer Ingelheim, on behalf of its partnership with $LLY, announced that they will create a model to predict the three major outcomes associated with type 2 diabetes. The new model will allow to predict the complications from cardiovascular death, kidney failure and hospitalization for heart failure.

$GILD {{ '2017-09-25T12:54:53+0000' | timeago}} • Announcement

$GILD said that the China Food and Drug Administration has approved Sovaldi,  a once-daily oral inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi is the first Gilead HCV medicine approved in China. Sovaldi received marketing approval from the US FDA in 2013 and the European Commission in 2014.

$AGN {{ '2017-09-25T12:23:08+0000' | timeago}} • Announcement

$AGN has authorized a new $2Bil share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually. The company also affirmed its 3Q17 revenue projection, which was issued on Aug 3, 2017.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$MDT {{ '2017-09-18T13:29:52+0000' | timeago}} • Announcement

$MDT announced FDA approval and U.S. launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow.

$GILD {{ '2017-09-15T13:21:02+0000' | timeago}} • Announcement

$GILD announced the pricing of senior unsecured notes in an aggregate principal amount of $3Bil, in an underwritten, registered public offering. The offering is expected to close September 21, 2017, subject to customary closing conditions. $GILD intends to use the net proceeds from the offering to finance a portion of the Kite acquisition.

$LIVN {{ '2017-09-14T20:47:42+0000' | timeago}} • Announcement

$LIVN intends to invest in inorganic opportunities within adjacent and underserved markets. The company expects to achieve revenue growth in the mid-single-digits in the near term and high-single-digits in the long term. $LIVN anticipates compounded annual earnings per share growth in the low- to mid-teens from 2017 to 2022.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$HAE {{ '2017-09-14T13:00:54+0000' | timeago}} • Announcement

$HAE, a healthcare company, announced the appointment of David Wilson as President of Plasma Business Unit, effective Sept 18, 2017. He was the President of Cordis and is a proven business leader with over 20 years of experience in senior leadership roles at medical technology companies.

$LLY {{ '2017-09-12T14:09:14+0000' | timeago}} • Announcement

$LLY announced that Jardiance tablets reduced the risk of cardiovascular death in people with Type 2 diabetes and established cardiovascular disease independent of blood sugar control. Jardiance also reduced the risk of cardiovascular death compared to placebo regardless of background Metformin or Sulfonylurea use.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$LH {{ '2017-09-11T20:39:56+0000' | timeago}} • Announcement

$LH announced that for the period of Sept 11, 2017 to March 9, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 will accrue contingent cash interest at a rate of 0.125% of the average market price of a Zero Coupon Note for the five trading days ended Sept 8, 2017. The payment of contingent cash interest is expected on March 9, 2018.

$LLY {{ '2017-09-11T15:56:35+0000' | timeago}} • Announcement

$LLY  to present data for Olumiant (baricitinib) for the treatment of moderate-to-severe atopic dermatitis at the annual European Academy of Dermatology and Venereology Congress (EADV) in Geneva during Sept 13-17, 2017. Lilly is also set to present data for its psoriasis drug Taltz in EADV.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, August 3 2017 - 12:00pm
GMED (Globus Medical, Inc.)
Wednesday, August 2 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
RMD (ResMed Inc.)
Tuesday, August 1 2017 - 8:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
EW (Edwards Lifesciences Corp.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
LH (Laboratory Corp. of America Holdings)
Wednesday, July 26 2017 - 1:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CNC (Centene Corp.)
Tuesday, July 25 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like